Cytokinetics' (CYTK) Redwood-HCM Top-line Results 'Deliver on All Fronts' - Analyst

Cytokinetics (CYTK) Prices 10M Share Offering at $27.5/sh

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $27.50 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be $275 million. The offering is expected to close on July 23, 2021, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an... More

Cytokinetics (CYTK) PT Raised to $44 at JMP Securities, Following Clinical Business Update

JMP Securities analyst Jason N. Butler raised the price target on Cytokinetics (NASDAQ: CYTK) to $44.00 (from $26.00) while maintaining a Market Outperform rating.

Cytokinetics (CYTK) PT Raised to $42 at Piper Sandler, Following Clinical Business Update

Piper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $42.00 (from $25.00) while maintaining a Overweight rating.

Cytokinetics (CYTK) PT Raised to $53 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $53.00 (from $41.00) while maintaining a Buy rating.

Cytokinetics (CYTK) PT Raised to $54 at Raymond James

Raymond James analyst Dane Leone raised the price target on Cytokinetics (NASDAQ: CYTK) to $54.00 (from $37.00) while maintaining a Outperform rating.

Cytokinetics (CYTK) PT Raised to $48 at Needham & Company

Needham & Company analyst Chad Messer raised the price target on Cytokinetics (NASDAQ: CYTK) to $48.00 (from $33.00) while maintaining a Buy rating.

Pre-Open Stock Movers 07/19: (NRXP) (CYTK) (AEHR) Higher; (RCAT) (NCLH) (CCL) Lower (more...)

Pre-Open Stock Movers:

NRx Pharmaceuticals (Nasdaq: NRXP) 48.9% HIGHER; will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10:10 EST. The presentation identifies a statistically significant effect of ZYESAMI (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19. In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the... More

Cytokinetics (CYTK) Announces Positive Topline Results of Redwood-HCM

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2... More